GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » ROCE %

Agentix (Agentix) ROCE % : 0.00% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Agentix ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Agentix's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.


Agentix ROCE % Historical Data

The historical data trend for Agentix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix ROCE % Chart

Agentix Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23
ROCE %
Get a 7-Day Free Trial Premium Member Only - - - - -

Agentix Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Agentix ROCE % Calculation

Agentix's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2023 )  (A: Aug. 2021 )(A: Mar. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2023 )  (A: Aug. 2021 )(A: Mar. 2023 )
=-1.372/( ( (0.051 - 0.607) + (0.261 - 2.511) )/ 2 )
=-1.372/( (-0.556+-2.25)/ 2 )
=-1.372/-1.403
=97.79 %

Agentix's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=0.04/( ( (0.334 - 3.149) + (0.112 - 2.958) )/ 2 )
=0.04/( ( -2.815 + -2.846 )/ 2 )
=0.04/-2.8305
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Agentix  (OTCPK:AGTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Agentix ROCE % Related Terms

Thank you for viewing the detailed overview of Agentix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Agentix (Agentix) Business Description

Traded in Other Exchanges
N/A
Address
32932 Pacific Coast Highway, Suite 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. It is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space.
Executives
Thomas E Puzzo 10 percent owner 4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter director, 10 percent owner, officer: President, CEO, CFO, Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc 10 percent owner 320 PARK AVE, NEW YORK NY 10022
Scott B Stevens director, officer: President and Director 9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen director, officer: Secretary and Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius director, 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix (Agentix) Headlines

No Headlines